15038 studies
Critical limb ischemia (CLI) represents a severe vascular complication of type 2 diabetes, primarily driven by impaired angiogenic capacity, and frequently results in limb amputation or mortality. Here, we investigated the therapeutic potential of ti…
The year 2025 represented a turning point in metabolic research, marked by advances that combined unprecedented clinical efficacy with deep mechanistic insight. Landmark obesity trials redefined therapeutic expectations, with head-to-head and combina…
OBJECTIVE: Obesity is a chronic disease that results in increased morbidity and mortality if left untreated. Tirzepatide is a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist approved in the United States for the…
BACKGROUND: Overweight and obesity are increasingly common in adults with type 1 diabetes (T1D), contributing to insulin resistance, higher insulin requirements, and greater cardiometabolic burden. Tirzepatide, a dual glucose-dependent insulinotropic…
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual incretin agonist tirzepatide have demonstrated cardiometabolic benefits in cardiovascular outcome trials, but their effects on limb outcomes in peripheral artery disease (PAD) re…
BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive disease continuum linking metabolic risk factors with cardiovascular and kidney disease. Patients in early CKM stages (stages 1-2) represent a critical therapeutic wi…
OBJECTIVE: Ketoacidosis is a critical adverse event requiring close clinical monitoring. Based on the Adverse Event Reporting System (FAERS) database of the U.S. Food and Drug Administration (FDA), this study aimed to identify the drugs with the clos…
BACKGROUND: Compounded versions of tirzepatide are widely available in the U.S. in the form of fixed‑dose combinations of tirzepatide and various analogs of vitamin B12. These combinations are mass marketed in the U.S. and other countries as comparab…
BACKGROUND: More than 80% of patients with heart failure with preserved ejection fraction (HFpEF) are overweight or obese. However, cost-effective treatments that target both conditions remain limited. OBJECTIVES: The goal of this study was to evalua…
INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1. Despite efficacy, GLP-1 RAs are associated with adverse reactions across mu…
PURPOSE: This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programme and methodological…
INTRODUCTION: Tirzepatide has been associated with significant reductions in body weight in randomized clinical trials. However, real-world evidence evaluating the multisystemic effects of tirzepatide across the cardio-metabolic-kidney (CKM) continuu…
AIMS: To evaluate 6-month weight-loss outcomes, treatment persistence, and safety of low- to moderate-dose tirzepatide in a real-world clinical setting. METHODS: This multicentre retrospective observational study evaluated adults with obesity who ini…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, howeve…
INTRODUCTION: obesity is a chronic and relapsing disease. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated weight loss exceeding 20 % at higher doses. However, real-world data remain limited, particularly regarding body compositio…
Obesity is a chronic, highly prevalent disease affecting nearly one-third of the global population and represents a major independent risk factor for heart failure (HF), particularly heart failure with preserved ejection fraction (HFpEF). Excess adip…